(Q31536804)

2 July 2017

title

A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation (English)

1 reference

2 July 2017

E Olavarria

1

1 reference

2 July 2017

M Hassan

2

1 reference

2 July 2017

A Eades

3

1 reference

2 July 2017

C Nilsson

4

1 reference

2 July 2017

A Timms

5

1 reference

2 July 2017

J Matthews

6

1 reference

2 July 2017

C Craddock

7

1 reference

2 July 2017

E Kanfer

8

1 reference

2 July 2017

J Apperley

9

1 reference

2 July 2017

J Goldman

10

1 reference

2 July 2017

publication date

1 November 2000

1 reference

2 July 2017

1 reference

2 July 2017

volume

14

1 reference

2 July 2017

issue

11

1 reference

2 July 2017

page(s)

1954-1959

1 reference

Aspects concerning busulfan pharmacokinetics and bioavailability

2 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401921

7 January 2021

Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401921

7 January 2021

Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401921

7 January 2021

Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401921

7 January 2021

High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401921

7 January 2021

Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401921

7 January 2021

Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401921

7 January 2021

Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401921

7 January 2021

High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401921

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401921

1 reference

7 January 2021

Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401921

7 January 2021

Liposomal busulphan: bioavailability and effect on bone marrow in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401921

7 January 2021

Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2401921

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2401921

1 reference

Dimensions Publication ID

2 July 2017

1052635632

0 references

1 reference